Summary & Overview
HCPCS J1620: Gonadorelin Hydrochloride Injection, 100 mcg
HCPCS Level II code J1620 denotes an injection of gonadorelin hydrochloride, billed per 100 mcg. Gonadorelin is used primarily for diagnostic evaluation of pituitary–gonadal axis function and in select reproductive endocrinology settings; accurate coding ensures correct identification of the drug and supports appropriate claims processing for injectable diagnostic agents. Nationally, consistent use of J1620 affects medical billing for outpatient diagnostic procedures and fertility/endocrine services where gonadorelin is indicated.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the medication, payer coverage landscape, common billing modifiers associated with injectable drugs, and benchmark considerations for unitization and site-of-service variability. The report summarizes coding specificity, common billing scenarios, and claims considerations relevant to providers, billing teams, and policy analysts seeking clarity on how J1620 is applied in outpatient and clinic-based settings.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J1620 represents an injection of gonadorelin hydrochloride, billed per 100 mcg unit. This medication is a gonadotropin-releasing hormone (GnRH) analog used in diagnostic testing of pituitary and gonadal function and in certain fertility or endocrinology procedures.
-
Service type: Injection medication administration for diagnostic and endocrinology indications
-
Typical site of service: Outpatient clinic, hospital outpatient department, physician office, or specialized reproductive endocrinology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent referred to an outpatient infusion clinic, fertility center, or endocrinology practice for administration of diagnostic or therapeutic gonadorelin hydrochloride (J1620) for evaluation or management of reproductive endocrine disorders. Common indications include evaluation of hypothalamic-pituitary-gonadal axis function (gonadotropin-releasing hormone stimulation test) and short-term therapeutic use to trigger luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release in controlled fertility or diagnostic procedures.
The clinical workflow: a provider (endocrinologist, reproductive endocrinologist, or pediatric endocrinologist) orders J1620 using the specified dose per 100 mcg vial. Nursing staff verify the order, review allergies and consent, prepare the medication under aseptic technique, and administer as a subcutaneous or intravenous bolus per protocol. Vital signs and monitoring are performed before and after administration. For stimulation testing, baseline labs (LH, FSH, estradiol or testosterone) are drawn immediately prior to administration and at protocol-specified intervals after injection. For fertility procedures, medication administration is coordinated with ultrasound monitoring and other hormonal therapies. Documentation includes indication, dose (per 100 mcg unit), route, site, lot number, and patient response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|